A Vancouver-based micro cap saw it’s shares rally strongly on Wednesday after it was announced that the company has entered into a long-term distribution agreement with Mind Medicine Australia (“MMA”), a leading charitable organization and patient advocacy group seeking to alleviate suffering caused by %MentalIllness in Australia by expanding access to psychedelic assisted therapies in highly regulated clinical environments, to supply its MDMA formulation, OPTI-MHCL, and GMP psilocybin capsules, according to the release.
Shares of %OptimiHealth () rallied strongly up to $0.255/share (+27.50%) following the announcement. This move is a breath of fresh air for long term shareholders that have been riding the downtrend over the last few months.
Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing and distribution of agrifoods. It also intends to cultivate, extract, process and distribute high-quality strains of fungi products at its facilities located in Princeton, British Columbia.